ATE237346T1 - Gebrauch von galanin um nervenschäden zu reparieren - Google Patents

Gebrauch von galanin um nervenschäden zu reparieren

Info

Publication number: ATE237346T1
Authority: AT; Austria
Prior art keywords: galanin; treatment; nerve damage; supression; pain
Prior art date: 1996-07-24

Application number

AT97932939T

Other languages

English (en)

Inventor

David Wynick

Original Assignee

Neurotargets Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-07-24

Filing date

1997-07-24

Publication date

2003-05-15

1996-07-24 Priority claimed from GBGB9615551.0A external-priority patent/GB9615551D0/en

1996-11-15 Priority claimed from GBGB9623869.6A external-priority patent/GB9623869D0/en

1997-07-24 Application filed by Neurotargets Ltd filed Critical Neurotargets Ltd

2003-05-15 Application granted granted Critical

2003-05-15 Publication of ATE237346T1 publication Critical patent/ATE237346T1/de

Links

208000028389 Nerve injury Diseases 0.000 title abstract 2
230000008764 nerve damage Effects 0.000 title abstract 2
101800002068 Galanin Proteins 0.000 abstract 5
102000019432 Galanin Human genes 0.000 abstract 4
SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 abstract 4
230000036407 pain Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010002091 Anaesthesia Diseases 0.000 abstract 1
206010036832 Prolactinoma Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
230000037005 anaesthesia Effects 0.000 abstract 1
238000001949 anaesthesia Methods 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000019771 cognition Effects 0.000 abstract 1
238000011813 knockout mouse model Methods 0.000 abstract 1
210000005036 nerve Anatomy 0.000 abstract 1
208000005877 painful neuropathy Diseases 0.000 abstract 1
208000030153 prolactin-producing pituitary gland adenoma Diseases 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Environmental Sciences (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biodiversity & Conservation Biology (AREA)
Animal Husbandry (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Obesity (AREA)
Hematology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)

AT97932939T 1996-07-24 1997-07-24 Gebrauch von galanin um nervenschäden zu reparieren ATE237346T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9615551.0A GB9615551D0 (en)	1996-07-24	1996-07-24	Galanin
GBGB9623869.6A GB9623869D0 (en)	1996-11-15	1996-11-15	Galanin
PCT/GB1997/001991 WO1998003059A1 (en)	1996-07-24	1997-07-24	Galanin

Publications (1)

Publication Number	Publication Date
ATE237346T1 true ATE237346T1 (de)	2003-05-15

Family

ID=26309752

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT02028584T ATE457125T1 (de)	1996-07-24	1997-07-24	Verwendung eines galanin-agonisten in der herstellung eines medikaments zur verbesserung des gedächtnisses und anderer cognitiver funktionen
AT97932939T ATE237346T1 (de)	1996-07-24	1997-07-24	Gebrauch von galanin um nervenschäden zu reparieren

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT02028584T ATE457125T1 (de)	1996-07-24	1997-07-24	Verwendung eines galanin-agonisten in der herstellung eines medikaments zur verbesserung des gedächtnisses und anderer cognitiver funktionen

Country Status (11)

Country	Link
US (1)	US20030009777A1 (de)
EP (2)	EP1342410B1 (de)
JP (1)	JP2000516212A (de)
AT (2)	ATE457125T1 (de)
AU (1)	AU3630297A (de)
DE (2)	DE69721005T2 (de)
DK (2)	DK1342410T3 (de)
ES (2)	ES2340984T3 (de)
GB (1)	GB2331301C (de)
PT (2)	PT918455E (de)
WO (1)	WO1998003059A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997026853A2 (en)	1996-01-24	1997-07-31	Synaptic Pharmaceutical Corporation	Dna encoding galanin galr2 receptors and uses thereof
US6329197B2 (en)	1996-10-09	2001-12-11	Synaptic Pharmaceutical Corporation	DNA encoding galanin GALR3 receptors and uses thereof
EP1421214A4 (de) *	2001-08-27	2005-11-02	Tularik Inc	Amplifizierte onkogene und deren rolle bei krebs
WO2003070950A1 (fr) *	2002-02-22	2003-08-28	Takeda Chemical Industries, Ltd.	Nouvel adn et utilisation correspondante
GB0403509D0 (en) *	2004-02-17	2004-03-24	Neuro Targets Ltd	Galanin receptors and brain injury
CA2580690A1 (en) *	2004-10-21	2006-05-04	Transtech Pharma, Inc.	Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
GB0523550D0 (en)	2005-11-18	2005-12-28	Hunter Fleming Ltd	Therapeutic uses of steroidal compounds
WO2008086573A1 (en) *	2007-01-19	2008-07-24	Howard Florey Institute Of Experimental Physiology And Medicine	Use of galanin in a method of treating neurodegenerative diseases or conditions
EP2187910A2 (de) *	2007-09-11	2010-05-26	Mondobiotech Laboratories AG	Verwendung von band 3 protein (824-829) und/oder melanozyten-stimulierendem hormonfreisetzungs, hemmendem faktor als therapeutisches mittel bei der behandlung von infektionen mit pseudomonas aeruginosa
AU2008361604A1 (en) *	2008-09-09	2010-03-18	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
ES2883838A1 (es) *	2020-06-04	2021-12-09	Univ Malaga	Prevencion y/o tratamiento del deterioro cognitivo asociado a sindromes de demencia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1350792A (en) *	1991-01-16	1992-08-27	General Hospital Corporation, The	Human galanin
AU1462692A (en) *	1991-02-25	1992-09-15	Board Of Regents Of The University Of Washington, The	Methods for detecting galanin antagonists
WO1992015681A1 (en) *	1991-03-06	1992-09-17	Garvan Institute Of Medical Research	HUMAN GALANIN, cDNA CLONES ENCODING HUMAN GALANIN AND A METHOD OF PRODUCING HUMAN GALANIN
SE9101472D0 (sv)	1991-05-15	1991-05-15	Trion Forskning & Utveckling	Galanin antagonist
JPH06172387A (ja) *	1992-12-11	1994-06-21	Aibaitsu Kk	合成ペプチド誘導体
US6225282B1 (en) *	1996-01-05	2001-05-01	Genentech, Inc.	Treatment of hearing impairments
WO1997026853A2 (en) *	1996-01-24	1997-07-31	Synaptic Pharmaceutical Corporation	Dna encoding galanin galr2 receptors and uses thereof

1997
- 1997-07-24 AT AT02028584T patent/ATE457125T1/de not_active IP Right Cessation
- 1997-07-24 EP EP02028584A patent/EP1342410B1/de not_active Expired - Lifetime
- 1997-07-24 EP EP97932939A patent/EP0918455B1/de not_active Expired - Lifetime
- 1997-07-24 AT AT97932939T patent/ATE237346T1/de not_active IP Right Cessation
- 1997-07-24 DE DE69721005T patent/DE69721005T2/de not_active Expired - Lifetime
- 1997-07-24 PT PT97932939T patent/PT918455E/pt unknown
- 1997-07-24 US US09/230,463 patent/US20030009777A1/en not_active Abandoned
- 1997-07-24 DE DE69739760T patent/DE69739760D1/de not_active Expired - Lifetime
- 1997-07-24 WO PCT/GB1997/001991 patent/WO1998003059A1/en not_active Ceased
- 1997-07-24 DK DK02028584.7T patent/DK1342410T3/da active
- 1997-07-24 DK DK97932939T patent/DK0918455T3/da active
- 1997-07-24 GB GB9901264A patent/GB2331301C/en not_active Expired - Fee Related
- 1997-07-24 AU AU36302/97A patent/AU3630297A/en not_active Abandoned
- 1997-07-24 ES ES02028584T patent/ES2340984T3/es not_active Expired - Lifetime
- 1997-07-24 JP JP10506711A patent/JP2000516212A/ja not_active Ceased
- 1997-07-24 PT PT02028584T patent/PT1342410E/pt unknown
- 1997-07-24 ES ES97932939T patent/ES2196349T3/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
GB9901264D0 (en)	1999-03-10
DK1342410T3 (da)	2010-05-31
AU3630297A (en)	1998-02-10
PT918455E (pt)	2003-09-30
WO1998003059A1 (en)	1998-01-29
GB2331301A (en)	1999-05-19
JP2000516212A (ja)	2000-12-05
DK0918455T3 (da)	2003-08-04
ATE457125T1 (de)	2010-02-15
EP0918455B1 (de)	2003-04-16
GB2331301B (en)	2001-02-14
EP1342410A2 (de)	2003-09-10
ES2196349T3 (es)	2003-12-16
US20030009777A1 (en)	2003-01-09
EP1342410A3 (de)	2003-12-10
GB2331301C (en)	2005-05-22
EP0918455A1 (de)	1999-06-02
EP1342410B1 (de)	2010-02-10
DE69721005D1 (de)	2003-05-22
PT1342410E (pt)	2010-05-11
DE69721005T2 (de)	2004-06-09
ES2340984T3 (es)	2010-06-14
DE69739760D1 (de)	2010-03-25

Legal Events

Date

Code

Title

Description

2004-01-15

UEP

Publication of translation of european patent specification

Ref document number: 0918455

Country of ref document: EP

2012-04-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE293989T1 (de)	2005-05-15	Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DE69833971D1 (de)	2006-05-11	Verfahren zur behandlung von alzheimerschen krankheit
ATE218854T1 (de)	2002-06-15	Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
DE60031396D1 (de)	2006-11-30	Zubereitung zur behandlung von einer neurologischen erkrankung
ATE433973T1 (de)	2009-07-15	Azolylaminoazine als inhibitoren von proteinkinasen
ATE363290T1 (de)	2007-06-15	Cd40 antagonist zur behandlung von psoriasis
TR200002773T2 (tr)	2001-11-21	Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE60335244D1 (de)	2011-01-20	Behandlung von verletzungen des zentralen nervensystems
BRPI0414277A (pt)	2006-11-07	métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
BR9811780A (pt)	2000-09-12	Método de aumento de volume ósseo usando agonistas seletivos fp não ocorrendo naturalmente
BR0015416A (pt)	2002-07-16	Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
ATE237346T1 (de)	2003-05-15	Gebrauch von galanin um nervenschäden zu reparieren
EA200200132A1 (ru)	2002-06-27	СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
YU13301A (sh)	2005-06-10	Muskarinski agonisti i antagonisti
DE69711078D1 (de)	2002-04-18	Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BR0012327A (pt)	2002-07-02	Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
FR2825273B1 (fr)	2006-11-24	Composition pour le traitement des signes cutanes du vieillissement
ATE326265T1 (de)	2006-06-15	Zusammensetzung aus dhea und calcitonin zur behandlung von subnormaler knochen-mineraldichte
DE69932922D1 (de)	2006-10-05	Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
BR0012921A (pt)	2002-06-18	Compostos calcilìticos
PT1152757E (pt)	2005-09-30	Inibidores de mmp no amolecimento do tecido conjuntivo
ATE333287T1 (de)	2006-08-15	Prophylaxe und behandlung von autoimmunen entmyelinisierungserkrankungen durch fas- antagonisten
DE69941134D1 (de)	2009-08-27	Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
ATE345138T1 (de)	2006-12-15	Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
ATE402147T1 (de)	2008-08-15	1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen